Press Releases from 2012
Reinach, Switzerland, 20 December 2012 – Evolva Holding SA (SIX: EVE) today announces it has had a positive meeting with the German regulatory authority BfArM regarding the further clinical steps for EV-077.
Evolva gains first on-market product, consolidates technology strengths
Associated reprioritisation of Evolva’s development portfolio
Reinach, Switzerland, 26 September 2012 – Evolva Holding SA (SIX: EVE) today announced that Roquette Frères SA (Roquette) has confirmed that Evolva has achieved the first milestone in their collaboration that was announced in January 2012.
Reinach, Switzerland, 10 September 2012 - Evolva Holding SA (SIX: EVE) presented extensive preclinical data on EV-035 at ICAAC, the world’s premier international conference on antimicrobial agents and infectious diseases.
Reinach, Switzerland, 29 August 2012 – Evolva Holding SA (SIX: EVE) today announced its financial results for the period 1 January to 30 June 2012. The condensed accounts are available on Evolva’s website.
Reinach, Switzerland, 28 August 2012 - Evolva Holding SA (SIX: EVE) today announces further data for the first 32 patients enrolled in the Phase IIa study of its investigational drug, EV-077, a novel, reversible antagonist of isoprostanes and prostanoids. 16 patients received EV-077 and 16 patients received placebo.
Further data to be presented at ESC Congress 2012
Reinach, Switzerland, 17 August 2012 – Evolva Holding SA (SIX: EVE) today announced top-line results for the first 32 patients enrolled in the Phase IIa study of its investigational drug, EV-077, a novel, reversible antagonist of isoprostanes and prostanoids.
Reinach, Switzerland, 21 June 2012 – Evolva Holding SA (SIX: EVE) today announced that International Flavors & Fragrances Inc. (IFF) has confirmed that Evolva has achieved the first milestone in their collaboration that was announced in January 2011.
Reinach, Switzerland, 9 May 2012 – The Annual General Meeting of Evolva Holding SA (SIX: EVE) has approved all proposals put forward by the Board of Directors.
- 1 of 2
- next ›
Strategy
Products
Legacy Products
Technology
